Commodore Capital LP Cogent Biosciences, Inc. Transaction History
Commodore Capital LP
- $1.16 Billion
- Q1 2024
A detailed history of Commodore Capital LP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Commodore Capital LP holds 6,425,000 shares of COGT stock, worth $54.2 Million. This represents 3.73% of its overall portfolio holdings.
Number of Shares
6,425,000
Previous 5,566,026
15.43%
Holding current value
$54.2 Million
Previous $32.7 Million
31.92%
% of portfolio
3.73%
Previous 3.42%
Shares
11 transactions
Others Institutions Holding COGT
# of Institutions
159Shares Held
102MCall Options Held
197KPut Options Held
102K-
Kynam Capital Management, LP Princeton, NJ8.5MShares$71.7 Million5.99% of portfolio
-
State Street Corp Boston, MA7.63MShares$64.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.69MShares$56.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct6.68MShares$56.3 Million0.11% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.21MShares$52.4 Million4.4% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $554M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...